Antibiotic therapy for chorioamnionitis to reduce the global burden of associated disease

Clark Johnson, Rebecca R. Adami, Azadeh Farzin

Research output: Contribution to journalShort survey

Abstract

Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.

Original languageEnglish (US)
Article number97
JournalFrontiers in Pharmacology
Volume8
Issue numberMAR
DOIs
StatePublished - Mar 14 2017

Fingerprint

Chorioamnionitis
Anti-Bacterial Agents
Infant Mortality
Morbidity
Therapeutics
Developed Countries
Mothers
Global Burden of Disease
Parturition
Delivery of Health Care

Keywords

  • Chorioamnionitis
  • Global maternal health
  • Intraamniotic infection
  • Intrapartum antibiotics
  • Neonatal sepsis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antibiotic therapy for chorioamnionitis to reduce the global burden of associated disease. / Johnson, Clark; Adami, Rebecca R.; Farzin, Azadeh.

In: Frontiers in Pharmacology, Vol. 8, No. MAR, 97, 14.03.2017.

Research output: Contribution to journalShort survey

@article{76a24071e59c44308478a15ab0d4140f,
title = "Antibiotic therapy for chorioamnionitis to reduce the global burden of associated disease",
abstract = "Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.",
keywords = "Chorioamnionitis, Global maternal health, Intraamniotic infection, Intrapartum antibiotics, Neonatal sepsis",
author = "Clark Johnson and Adami, {Rebecca R.} and Azadeh Farzin",
year = "2017",
month = "3",
day = "14",
doi = "10.3389/fphar.2017.00097",
language = "English (US)",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Antibiotic therapy for chorioamnionitis to reduce the global burden of associated disease

AU - Johnson, Clark

AU - Adami, Rebecca R.

AU - Farzin, Azadeh

PY - 2017/3/14

Y1 - 2017/3/14

N2 - Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.

AB - Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.

KW - Chorioamnionitis

KW - Global maternal health

KW - Intraamniotic infection

KW - Intrapartum antibiotics

KW - Neonatal sepsis

UR - http://www.scopus.com/inward/record.url?scp=85016155074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016155074&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00097

DO - 10.3389/fphar.2017.00097

M3 - Short survey

C2 - 28352229

AN - SCOPUS:85016155074

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 97

ER -